Vixarelimab OSMRβ Antibody for Ulcerative Colitis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for moderate to severe ulcerative colitis (UC) have limited efficacy, with remission rates of only 20%-30% and are associated with serious side effects such as infections, infusion reactions, and malignancies.
Innovation Solution
The use of vixarelimab, a fully human monoclonal antibody targeting oncostatin M receptor-beta (OSMRβ), to inhibit the OSM/OSMRβ signaling pathway, thereby reducing inflammation in the gastrointestinal tract.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current advanced therapies (anti-TNF, anti-integrin, JAK inhibitors) are used to treat moderate to severe UC, then disease modification and mucosal healing are achieved, but serious side effects occur including infections, infusion reactions, cardiovascular events, thrombosis, and malignancies
Solution Approach 1:
The patent applies parameter changes by switching from existing therapeutic targets (TNF, integrins, JAK pathways) to a novel target (OSMRβ cytokine pathway). This fundamental parameter change in the molecular target enables alternative disease modification through inhibition of OSM and IL-31 signaling, achieving therapeutic efficacy while avoiding the side effect profile associated with current therapies
Solution Approach 2:
The patent uses a monoclonal antibody as an intermediary substance to block the OSMRβ cytokine pathway. This antibody mediator specifically inhibits the interaction between OSM/IL-31 and their receptors, providing a targeted mechanism to reduce inflammation and achieve mucosal healing without the broad immunosuppression that causes side effects in current therapies
2Reliability
If current advanced therapies are used to achieve disease modification, then remission is achieved in some patients, but only 20%-30% remission rates are obtained in induction trials
Solution Approach 1:
The patent achieves improved productivity (remission rate) by changing the therapeutic parameter from existing targets to the OSMRβ pathway. This novel target engagement provides a different mechanism of action that may overcome treatment resistance and achieve higher remission rates compared to current therapies
Solution Approach 2:
The patent applies inversion by targeting a different cytokine pathway (OSM/IL-31 via OSMRβ) rather than the conventional targets (TNF, integrins). This reverse approach to target selection provides an alternative mechanism that may be effective in patients who have failed or are intolerant to current standard therapies
3Reliability
If loss of response to current medications occurs in 22%-29% of patients, then initial treatment efficacy is achieved, but durable treatment is lost over time
Solution Approach 1:
The patent uses a monoclonal antibody intermediary to target the OSMRβ pathway, providing a novel mechanism of action that may prevent loss of response. By engaging a different cytokine pathway not targeted by current therapies, the treatment maintains its mechanism of action over time without developing the same resistance patterns as existing medications
Data Source
AI summary
This disclosure relates to methods, uses, and compositions (e.g., articles of manufacture and kits) comprising an anti-OSMRβ antibody, such as vixarelimab, for the treatment of inflammatory gastrointestinal diseases associated with the oncostatin M (OSM) pathway (e.g., inflammatory bowel disease (IBD) (e.g., ulcerative colitis (UC (e.g., moderate to severe UC)) and Crohn's disease (CD)).